{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:39:58Z","timestamp":1794008398021,"version":"4.8.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T00:00:00Z","timestamp":1744848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","award":["MR\/V028375\/1"],"award-info":[{"award-number":["MR\/V028375\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["206602"],"award-info":[{"award-number":["206602"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"EC | Directorate-General for Employment, Social Affairs and Inclusion | European Social Fund","doi-asserted-by":"publisher","award":["RYC 2020\u2013029886-I\/ AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["RYC 2020\u2013029886-I\/ AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department for Health and Social Care"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>People with Post-Covid Condition (PCC) may demonstrate aberrant immune responses post-infection; however, serological follow-up studies are limited. We aim to compare SARS-CoV-2 serological responses to infection and vaccination in people who develop PCC versus those with an acute infection only. Participants (<jats:italic>n<\/jats:italic>\u2009=\u20092010) are a sub-cohort of the Virus Watch community cohort in England who provided monthly finger-prick serological samples. We compare the likelihood of post-infection seroconversion using logistic mixed models and the trajectories of anti-nucleocapsid (anti-N) and anti-spike (anti-S) antibodies using linear mixed models. Participants who developed PCC (<jats:italic>n<\/jats:italic>\u2009=\u2009394) have 1.8x the odds of post-infection seroconversion for anti-N antibodies compared to those with an acute infection only (<jats:italic>n<\/jats:italic>\u2009=\u20091616) (odds ratio= 1.81 (95% confidence interval (CI) 1.16-2.90); however, these results are moderated by vaccination status and variant \u2013 with differences observed in pre-Omicron, unvaccinated participants. Anti-N levels, however, were elevated within 200 days post-infection in people with PCC compared to those without, after accounting for variant and vaccination status. Vaccination response (anti-S) pre- or post-infection did not systematically differ between groups. People with PCC demonstrate persistently higher anti-N antibody levels following primary infection compared to those with an acute infection only. These findings extend emerging evidence around infection-related immune activation and PCC.<\/jats:p>","DOI":"10.1038\/s41467-025-58766-7","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:59:16Z","timestamp":1744919956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-nucleocapsid and anti-spike antibody trajectories in people with post-covid condition versus acute-only infections: a nested longitudinal case-control study within the Virus Watch prospective cohort"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4038-7460","authenticated-orcid":false,"given":"Sarah","family":"Beale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4100-4257","authenticated-orcid":false,"given":"Alexei","family":"Yavlinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5105-9836","authenticated-orcid":false,"given":"Gemma","family":"Moncunill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5097-2228","authenticated-orcid":false,"given":"Wing Lam Erica","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-6242","authenticated-orcid":false,"given":"Vincent Grigori","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0477-2767","authenticated-orcid":false,"given":"Jana","family":"Kovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0370-1430","authenticated-orcid":false,"given":"Ibrahim","family":"Abubakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0542-0816","authenticated-orcid":false,"given":"Robert W.","family":"Aldridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"58766_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol 21, 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol"},{"key":"58766_CR2","doi-asserted-by":"crossref","unstructured":"Bull-Otterson L. et al. Post\u2013COVID Conditions Among Adult COVID-19 Survivors Aged 18\u201364 and \u226565 Years \u2014 United States, March 2020\u2013November 2021. MMWR. Morbidity and Mortality Weekly Report, 71 (2022).","DOI":"10.15585\/mmwr.mm7121e1"},{"key":"58766_CR3","doi-asserted-by":"crossref","unstructured":"O\u2019Mahoney L. L. et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine. 55, 101762 (2023).","DOI":"10.1016\/j.eclinm.2022.101762"},{"key":"58766_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S1473-3099(23)00053-1","volume":"23","author":"A Iwasaki","year":"2023","unstructured":"Iwasaki, A. & Putrino, D. Why we need a deeper understanding of the pathophysiology of long COVID. Lancet Infect. Dis. 23, 393 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"58766_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/s41418-022-01015-x","volume":"29","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. Immune response in COVID-19: what is next? Cell Death Differ. 29, 1107\u20131122 (2022).","journal-title":"Cell Death Differ."},{"key":"58766_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2020","unstructured":"V\u2019kovski, P., Kratzel, A., Steiner, S., Stalder, H. & Thiel, V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol 19, 155\u2013170 (2020).","journal-title":"Nat. Rev. Microbiol"},{"key":"58766_CR7","doi-asserted-by":"crossref","unstructured":"Jackson C. B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 23, 3\u201320 (2022).","DOI":"10.1038\/s41580-021-00418-x"},{"key":"58766_CR8","doi-asserted-by":"crossref","unstructured":"Dai L., Gao G. F. Viral targets for vaccines against COVID-19. Nat. Rev. Immunol. 21, 73\u201382 (2021).","DOI":"10.1038\/s41577-020-00480-0"},{"key":"58766_CR9","doi-asserted-by":"crossref","unstructured":"Assis R. et al. Distinct SARS-CoV-2 antibody reactivity patterns elicited by natural infection and mRNA vaccination. NPJ vaccines. 6, 132 (2021)","DOI":"10.1038\/s41541-021-00396-3"},{"key":"58766_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijid.2022.07.053","volume":"123","author":"AMD Navaratnam","year":"2022","unstructured":"Navaratnam, A. M. D. et al. Nucleocapsid and spike antibody responses following virologically confirmed SARS-CoV-2 infection: an observational analysis in the Virus Watch community cohort. Int J. Infect. Dis. 123, 104 (2022).","journal-title":"Int J. Infect. Dis."},{"key":"58766_CR11","doi-asserted-by":"crossref","unstructured":"Phetsouphanh, C. et al. Improvement of immune dysregulation and health-related quality of life in individuals with long COVID at 24-months following SARS-CoV-2 infection. Nat. Commun. 15, 3315 (2024).","DOI":"10.1101\/2023.08.27.23294704"},{"key":"58766_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223936","volume":"14","author":"MA Limoges","year":"2023","unstructured":"Limoges, M. A. et al. SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-covid condition. Front Immunol. 14, 1223936 (2023).","journal-title":"Front Immunol."},{"key":"58766_CR13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/v15030701","volume":"15","author":"C Hackenbruch","year":"2023","unstructured":"Hackenbruch, C. et al. Elevated SARS-CoV-2-specific antibody levels in patients with post-COVID syndrome. Viruses 15, 701 (2023).","journal-title":"Viruses"},{"key":"58766_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3390\/vaccines10020165","volume":"10","author":"R Varnai","year":"2022","unstructured":"Varnai, R. et al. Serum level of anti-nucleocapsid, but not anti-spike antibody, is associated with improvement of long COVID symptoms. Vaccines 10, 165 (2022).","journal-title":"Vaccines"},{"key":"58766_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.ijid.2021.04.080","volume":"107","author":"C Gerhards","year":"2021","unstructured":"Gerhards, C. et al. Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescence from a COVID-19 infection. Int J. Infect. Dis. 107, 221\u2013227 (2021).","journal-title":"Int J. Infect. Dis."},{"key":"58766_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38869-1","volume":"13","author":"C Geismar","year":"2023","unstructured":"Geismar, C. et al. Symptom profiles of community cases infected by influenza, RSV, rhinovirus, seasonal coronavirus, and SARS-CoV-2 variants of concern. Sci. Rep. 13, 12511 (2023).","journal-title":"Sci. Rep."},{"key":"58766_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.809244","volume":"12","author":"P Mistry","year":"2022","unstructured":"Mistry, P. et al. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 12, 809244 (2022).","journal-title":"Front Immunol."},{"key":"58766_CR18","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1017\/S0950268824000748","volume":"152","author":"S Beale","year":"2024","unstructured":"Beale, S. et al. Long-term outcomes of SARS-CoV-2 variants and other respiratory infections: evidence from the Virus Watch prospective cohort in England. Epidemiol. Infect. 152, e77 (2024).","journal-title":"Epidemiol. Infect."},{"key":"58766_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2017","unstructured":"Lu, L. L., Suscovich, T. J., Fortune, S. M. & Alter, G. Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18, 46\u201361 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"58766_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-12495-0","volume":"7","author":"R Plomp","year":"2017","unstructured":"Plomp, R. et al. Subclass-specific IgG glycosylation is associated with markers of inflammation and metabolic health. Sci. Rep. 7, 1\u201310 (2017).","journal-title":"Sci. Rep."},{"key":"58766_CR21","doi-asserted-by":"publisher","first-page":"e048042","DOI":"10.1136\/bmjopen-2020-048042","volume":"11","author":"A Hayward","year":"2021","unstructured":"Hayward, A. et al. Risk factors, symptom reporting, healthcare-seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study. BMJ Open 11, e048042 (2021).","journal-title":"BMJ Open"},{"key":"58766_CR22","doi-asserted-by":"crossref","unstructured":"Byrne T. et al. Cohort profile: Virus Watch: Understanding community incidence, symptom profiles, and transmission of COVID-19 in relation to population movement and behaviour. Intel. J. Epidemiol. 52, e263\u2013e272 (2023).","DOI":"10.1093\/ije\/dyad087"},{"key":"58766_CR23","unstructured":"A clinical case definition of post COVID-19 condition by a Delphi consensus. (World Health Organization; 2021). Available from https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1."},{"key":"58766_CR24","unstructured":"UK Health Security Agency. COVID-19: The Green Book, chapter 14a. Available from: https:\/\/www.gov.uk\/government\/publications\/covid-19-the-green-book-chapter-14a (2020)."},{"key":"58766_CR25","unstructured":"US Food and Drug Administration. available from: roche diagnostics GmbH (2020). Elecsys Anti-SARS-CoV-2 S. https:\/\/diagnostics.roche.com\/gb\/en\/products\/lab\/elecsys-anti-sars-cov-2-s-cps-000616.html (2025)."},{"key":"58766_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-33550-z","volume":"13","author":"M Shrotri","year":"2022","unstructured":"Shrotri, M. et al. Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study. Nat. Commun. 13, 1\u201310 (2022).","journal-title":"Nat. Commun."},{"key":"58766_CR27","unstructured":"Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis. (2020)."},{"key":"58766_CR28","unstructured":"Public Health England. Evaluation of Roche Elecsys AntiSARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies (2024)."},{"key":"58766_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2021.114271","volume":"297","author":"E Riester","year":"2021","unstructured":"Riester, E. et al. Performance evaluation of the Roche Elecsys Anti-SARS-CoV-2 S immunoassay. J. Virol. Methods 297, 114271 (2021).","journal-title":"J. Virol. Methods"},{"key":"58766_CR30","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.cmi.2020.05.023","volume":"26","author":"J Van Elslande","year":"2020","unstructured":"Van Elslande, J. et al. Antibody response against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated immunoassays and three ELISAs. Clin. Microbiol Infect. 26, 1557 (2020).","journal-title":"Clin. Microbiol Infect."},{"key":"58766_CR31","unstructured":"UK Health Security Agency. COVID-19: guidance on protecting people defined on medical grounds as extremely vulnerable.: https:\/\/www.gov.uk\/government\/publications\/guidance-on-shielding-and-protectingextremely-vulnerable-persons-from-covid-19 (2020)."},{"key":"58766_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-32265-5","volume":"13","author":"RW Aldridge","year":"2022","unstructured":"Aldridge, R. W. et al. SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. Nat. Commun. 13, 1\u20138 (2022).","journal-title":"Nat. Commun."},{"key":"58766_CR33","doi-asserted-by":"publisher","unstructured":"Yavlinsky A. et al. Anti-spike antibody trajectories in individuals previously immunised with BNT162b2 or ChAdOx1 following a BNT162b2 booster dose. Wellcome Open Res. https:\/\/doi.org\/10.12688\/wellcomeopenres.17914.1 (2022).","DOI":"10.12688\/wellcomeopenres.17914.1"},{"key":"58766_CR34","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/oxfordjournals.aje.a112044","volume":"100","author":"O Miettinen","year":"1974","unstructured":"Miettinen, O. Confounding and effect-modification. Am. J. Epidemiol. 100, 350\u2013353 (1974).","journal-title":"Am. J. Epidemiol."},{"key":"58766_CR35","unstructured":"Christiansen-Lindquist L., Wall K. M. Effect Measure Modification and Statistical Interaction. Fundamentals of Epidemiology. (Springer Publishing Company; 2024)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58766-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58766-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T19:59:22Z","timestamp":1744919962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-58766-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["58766"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-58766-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,17]]},"assertion":[{"value":"18 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ACH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3686"}}